July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Evaluation of uveitic macular edema in the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Trial
Author Affiliations & Notes
  • Edmund Tsui
    F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Ophthalmology, University of California, San Francisco, San Francisco, California, United States
  • Sivakumar Rathinam
    Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India
  • Radhika Thundikandy
    Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India
  • Anuradha Kanakath
    Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India
  • S Balamurugan
    Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Pondicherry, India
  • R Vedhanayaki
    Uvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India
  • Lyndell L Lim
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, Victoria, Australia
  • Eric B Suhler
    Casey Eye Institute, Oregon Health and Science University, Oregon, United States
  • Hassan Aldhibi
    Division of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
  • John Alexander Gonzales
    F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Ophthalmology, University of California, San Francisco, San Francisco, California, United States
  • Thuy Doan
    F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Ophthalmology, University of California, San Francisco, San Francisco, California, United States
  • Jeremy Keenan
    F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Ophthalmology, University of California, San Francisco, San Francisco, California, United States
  • Caleb Ebert
    F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
  • Eric Kim
    F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
  • Travis C Porco
    F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Ophthalmology, University of California, San Francisco, San Francisco, California, United States
  • Nisha Acharya
    F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States
    Ophthalmology, University of California, San Francisco, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Edmund Tsui, None; Sivakumar Rathinam, None; Radhika Thundikandy, None; Anuradha Kanakath, None; S Balamurugan, None; R Vedhanayaki, None; Lyndell Lim, None; Eric Suhler, None; Hassan Aldhibi, None; John Gonzales, None; Thuy Doan, None; Jeremy Keenan, None; Caleb Ebert, None; Eric Kim, None; Travis Porco, None; Nisha Acharya, None
  • Footnotes
    Support  This study was supported by National Eye Institute Cooperative Agreement U10 EY021125 ( PI Dr. Acharya). The UCSF Department of Ophthalmology is supported by National Eye Institute grant EY06190 and an unrestricted grant from the Research to Prevent Blindness Foundation.
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3856. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Edmund Tsui, Sivakumar Rathinam, Radhika Thundikandy, Anuradha Kanakath, S Balamurugan, R Vedhanayaki, Lyndell L Lim, Eric B Suhler, Hassan Aldhibi, John Alexander Gonzales, Thuy Doan, Jeremy Keenan, Caleb Ebert, Eric Kim, Travis C Porco, Nisha Acharya; Evaluation of uveitic macular edema in the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Trial. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3856.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The First-line Antimetabolite as Steroid-sparing Treatment (FAST) Trial is a randomized comparative effectiveness trial to determine which treatment, methotrexate (MTX) 25mg once weekly or mycophenolate mofetil (MMF) 1.5g twice daily, is more effective as first-line corticosteroid-sparing treatment for patients with non-infectious intermediate, posterior, or panuveitis. As part of the FAST Trial, optical coherence tomography (OCT) imaging is obtained prospectively. We compare the outcomes of uveitic macular edema in the FAST Trial.

Methods : Patients were initiated on a standardized oral prednisone taper starting at 1 mg/kg and randomized to receive either oral MTX 25mg once weekly or oral MMF 1.5g twice daily. Patients underwent monthly clinical examinations and OCT imaging. OCT images were graded at the reading center for the presence or absence of macular edema. We included all patients with macular edema at baseline and excluded patients with a serous detachment in the setting of Vogt-Koyanagi-Harada (VKH) disease. Change in macular thickness and visual acuity (VA) between treatment groups was evaluated with a linear mixed effects model. The primary endpoint was 6 months.

Results : Of the 216 patients enrolled in the FAST Trial, after excluding eyes with serous detachment with VKH disease, there were n=42 eyes in the MTX group and n=55 eyes in the MMF group with baseline macular edema. In these eyes, baseline median logMAR VA was 0.40 (Snellen equivalent 20/50) and 0.38 (20/48) for the MTX and MMF groups, respectively. Median change in logMAR VA was -0.10 and -0.16 for patients in MTX and MMF groups, respectively (P=0.04). Final median logMAR VA was 0.20 (20/32) for both groups. Baseline median central subfield macular thickness was 359μm in the MTX group and 342μm in the MMF group. At 6 months, the median macular thickness decreased to 330μm with MTX and 309μm with MMF. The change in macular thickness was not significantly different between the two groups (P=0.95). At 6 months, 8 (19.0%) eyes in the MTX and 22 (40.0%) eyes in MMF groups had resolution of macular edema (P=0.06).

Conclusions : In eyes with uveitic macular edema, treatment with either MTX or MMF results in a similar decrease in macular thickness and rate of resolution of macular edema. Visual acuity improved in patients treated with either MTX or MMF and had similar visual acuities at the 6-month primary endpoint.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×